You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Blood and immune system conditions
  5. Blood and bone marrow cancers

Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma

  • Technology appraisal guidance
  • Reference number: TA226
  • Published:  22 June 2011
  • Guidance
  • Tools and resources
  • Information for the public
  • History

Lymphoma (follicular non-Hodgkin's ) - rituximab: comments on the ACD received from the public through the NICE website

Lymphoma (follicular non-Hodgkin's ) - rituximab: comments on the ACD received from the public through the NICE website
Lymphoma (follicular non-Hodgkin's ) - rituximab: comments on the ACD received from the public through the NICE website
24 May 2011
(66.59 Kb 19 sec)

Adobe Acrobat reader required.

  Adobe Acrobat reader required.

This page was last updated: 20 May 2011

Back to top